






Okoye, A. and Cordano, P. and Taylor, E.R. and Morgan, I.M. and 
Everett, R. and Campo, M.S. (2005) Human papillomavirus 16 L2 
inhibits the transcriptional activation function, but not the DNA 









Glasgow ePrints Service 
http://eprints.gla.ac.uk 
 1
Virus Research (2005) 108, 1-14 
 
 
Human papillomavirus 16 L2 inhibits the transcriptional 
activation function, but not the DNA replication function, of 
HPV16 E2  
 
A. Okoye1#, P. Cordano1#, E. R. Taylor1, I. M. Morgan1,  
R. Everett 2 and M. S. Campo1* 
 
1 Institute of Comparative Medicine, Division of Pathological Sciences, Glasgow 
University, Garscube Estate, Glasgow G61 1QH, Scotland, UK; 2 MRC Unit of 
Virology, Glasgow University, Church Street, Glasgow G11 5JR Scotland UK. 
 
Running title: Interaction between HPV-16 E2 and L2  
 
#These two authors contributed equally to the work 
 
Corresponding author, Institute of Comparative Medicine, Department of Veterinary 
Pathology, Glasgow University, Garscube Estate, Glasgow G61 1QH, Scotland, UK.  
FAX: +44 141 330 5602; e-mail : s.campo@vet.gla.ac.uk 
 2
Abstract 
In this study we analysed the outcome of the interaction between HPV-16 L2 and E2 
on the transactivation and DNA replication functions of E2. When E2 was expressed 
on its own, it transactivated a number of E2-responsive promoters but co-expression 
of L2 led to the down-regulation of the transcription transactivation activity of the E2 
protein. This repression is not mediated by an increased degradation of the E2 protein. 
In contrast, the expression of L2 had no effect on the ability of E2 to activate DNA 
replication in association with the viral replication factor E1. Deletion mutagenesis 
identified L2 domains responsible for binding to E2 (first 50 N-terminus amino acid 
residues) and down-regulating its transactivation function (residues 301-400).  The 
results demonstrate that L2 selectively inhibits the transcriptional activation property 
of E2 and that there is a direct interaction between the two proteins, although this is 
not sufficient to mediate the transcriptional repression. The consequences of the L2-
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1. Introduction 
Papillomaviruses (PV) are non-enveloped DNA viruses that infect stratified 
squamous epithelia in a wide spectrum of animals, and induce benign 
hyperproliferative lesions which occasionally progress to cancer (Shah and Howley, 
1995). After infection, the viral genome replicates in low copy number in the basal 
layers of the epithelium and starts expressing its non structural proteins, while high-
copy number productive replication and expression of the structural proteins takes 
place in the differentiating cells of the more superficial layers, leading to the assembly 
of infectious viral particles (Taichman and LaPorta, 1987).  
Replication of the viral genome is dependent on two non structural viral 
proteins, E1 and E2, which specifically bind the viral DNA (Chiang et al., 1992), and 
E1 and E2 are the only viral proteins necessary to initiate replication from ori, the 
viral origin of replication (Chow and Broker, 1994). Additionally E2 is a major 
transcriptional regulator of the viral early genes (Swindle et al., 1999; Yang et al., 
1991). 
E2 functions are mediated by its binding to numerous sites (BS) in the PV 
long control region (LCR). In the LCR of mucosal PV, including human 
papillomavirus type 16 (HPV-16), there are four BS (BS1-4) (Desaintes and Demeret, 
1996). Two of these sites are immediately upstream from the TATA box (BS1,2), 
separated from each other and from the TATA box by 3 or 4 base pairs (bp). Of the 
other two sites (BS3,4), one (BS3) is beside the E1 DNA binding site involved in the 
regulation of viral DNA replication, and one (BS4) is a further 300-400 bp upstream. 
In general, binding of E2 to BS1,2 causes transcriptional repression, while E2 binding 
to BS3,4 can lead to activation (Demeret et al., 1997). However, the precise effect of 
E2 on transcription, whether activation or repression, varies depending on the E2, 
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LCR and host cells (Bouvard et al., 1994; Demeret et al., 1994; Demeret et al., 1997; 
Thierry and Howley, 1991).    
In the bovine papillomavirus type 1 (BPV-1) system, co-expression of the 
minor structural protein L2 and E2 causes the redistribution of E2 into the dynamic 
nuclear substructures pro-myelocytic nuclear domains (ND10), leading to the 
suggestion that a major redistribution of viral components occurs during virion 
assembly (Day et al., 1998; Heino et al., 2000). Studies performed by Day and 
colleagues (Day et al., 1998) in a hamster fibroblast cell line, latently infected with 
multiple copies of autonomously replicating BPV genomes, have shown that 
expression of L2 is followed by a localisation of L2 to ND10 and a shift in the 
localisation of E2 into these domains. ND10 localisation has been observed also for 
HPV-11 E1 and E2 in transient DNA replication systems (Swindle et al., 1999), and 
for HPV-33 L2 (Florin et al., 2002). 
Despite the observed co-localisation of PV E2 and L2 to ND10, little is known 
about how expression of L2 affects E2.  Here we report that in the presence of HPV-
16 L2, HPV-16 E2 loses its transcriptional transactivation ability but not its origin-
dependent DNA replication activity. The loss of transactivation activity is 
accompanied by L2-induced proteasome-independent post-transcriptional down-
regulation of E2 in HaCaT cells but not in C33a cells. The domains of L2 responsible 
for E2 binding, inhibition of E2 transactivation and E2 degradation have been 
mapped. The implications of these results for the viral life cycle are discussed.  
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2. Materials and methods 
2.1. Cells. HaCaT cells are spontaneously immortalized keratinocytes and are 
routinely grown in Dulbecco’s modified Eagle medium High Glucose without 
calcium chloride (Life Technologies, UK), supplemented with 10% foetal calf serum, 
1 mM sodium pyruvate, 4 mM L-glutamine, 100 IU penicillin per ml, and 100 μg 
streptomycin per ml at 37ºC in 5% CO2. C33a cells are human cervical carcinoma 
cells grown in Dulbecco’s MEM with GlutaMAX-I 4500 mg/L D-Glucose with 
sodium pyruvate (Life Technologies), supplemented with 10% foetal calf serum, 100 
IU penicillin per ml, and 100 μg streptomycin per ml at 37ºC in 5% CO2.  
2.2. Plasmids: pCMV-E216 (Bouvard et al., 1994) contains the HPV16 DNA 
fragment from nt 2725 to 3852) cloned into the XbaI-SmaI sites of the 
cytomegalovirus immediate-early promoter/enhancer-based expression vector pCMV4 
(Del Vecchio et al., 1992). p16-L2 contains the HPV-16 L2 DNA sequence from nt 
4135 to 5656 inserted into pcDNA3 (Invitrogen, UK), and p16-HAL2 is p16-L2 with 
three copies of HA1 epitope (Lee et al., 1998) at the N-terminus of L2.  p18LCR-BS1 
is a pGL3 luciferase reporter plasmid that contains a HPV-18 LCR with four point 
mutations in the E2 binding site 1 introduced by PCR. p18LCR-BS1-3 is a pGL3 
luciferase reporter plasmid that contains the HPV-18 LCR with mutations in the E2 
binding sites 1 to 3. p18LCR-BS1-3 was derived from a CAT reporter plasmid, 
generously provided by F. Thierry (Thierry and Howley, 1991). Plasmid p18-6E2 
(kindly provided by K. Vance) is a luciferase reporter plasmid with six E2 binding 
sites, separated by 4 base pairs, linked to the HPV-18 promoter, ptk is a plasmid with 
the luciferase gene under the control of the tk promoter, and ptk6E2 is the same 
plasmid with the six E2 binding sites linked to the tk promoter (Vance et al., 1999). 
p16ori-m is a modification of plasmid p16ori (Del Vecchio et al., 1992) in which a 
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base change was introduced at nt 115 (T instead of C) to generate a Dpn I site (Boner 
et al., 2002).   
pGEX-4T-2 (Amersham Pharmacia Biotech, UK) encodes glutathione S-
transferase (GST). Full length L2 and 5’ or 3’ deleted ORFs were inserted into pGEX-
4T-2 to create GST-L2 fusion proteins with the GST moiety at the N-terminus of L2. 
Deletion mutagenesis of the L2 ORF was done by PCR.  
pEGFP-C1 (Clontech, UK) encodes the Green Fluorescent Protein (GFP). It 
was used to clone full length L2 and 5’ or 3’ deleted ORFs to generate GFP-L2 fusion 
proteins with the L2 moiety at the C-terminus of GFP. 
2.3. Antibodies for Western blot. The following primary antibodies were used: anti 
HPV-16 E2 mouse monoclonal antibody TVG261 (Hibma et al., 1995); mouse anti-
HA monoclonal antibody HA.11 (Cambridge Biosciences, UK); anti HPV-16 L2 
polyclonal rabbit serum (Gornemann et al., 2002) and anti GFP polyclonal rabbit 
serum SC-8334 (Santa Cruz Biotechnology, UK). The secondary antibodies used 
were GPR, a sheep anti-mouse Ig (Amersham Pharmacia Biotech) and anti rabbit IgG 
(Sigma, UK), both linked to horseradish peroxidase. For the detection of actin, mouse 
monoclonal antibody Ab-1 (Oncogene™, UK) and goat anti-mouse IgM-HRP (Santa 
Cruz Biotechnology) were used. 
2.4. Western blot analysis. Cells were seeded onto 100mm cell culture dishes at a 
density of 106 cells/dish and cultured overnight. The cells were transfected with 4μg 
pCMV-E216 and/or 4μg p16-HAL2 using Lipofectamine Plus™ Reagent (Life 
Technologies) or calcium phosphate as above. HaCaT-16E2 cells were identically 
transfected with p16-HAL2. Cells were harvested 24 h post-transfection, washed 
twice with cold PBS and then lysed on ice in 250 μl of SDS- lysis buffer (100 mM 
Tris-HCl, pH 6.8, 2% SDS, 2% glycerol), clarified by centrifugation for 10 min at 4ºC 
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and the supernatant was recovered. Protein concentration was determined by 
absorbance measurement at 280 nm. 10 μg of each sample were electrophoresed on 
Nu PAGE™ 4-12% Bis-Tris gel under denaturing conditions and transferred onto a 
nitrocellulose membrane (Invitrogen, UK). Membranes were either incubated with 
mAb TVG261 (dilution 1:250), anti-HA mAb HA.11 (dilution 1:1,000), anti HPV-16 
L2 serum (1:3,000), anti GFP serum (1:5,000) or mAb Ab-1 (dilution 1:20,000), 
followed by incubation with GPR or anti-rabbit IgG at a dilution 1:5,000. Western 
blots were developed by enhanced chemiluminescence (ECL, Amersham Pharmacia 
Biotech).  
For proteasomes inhibition studies, 16 hours after transfection, the cells were 
treated for 8 h with 5μM MG132, 12.5μM Lactacystin, 100μM ALLM or 100μM 
ALLN (Calbiochem, UK) before further processing.  
2.5. Luciferase reporter assays. Cells were seeded in 60mm plates and were 
transfected with 0.1μg of the reporter plasmids p18LCR-BS1and p18LCR-BS1-3, 
p18-6E2 and ptk6E2, using Lipofectamine Plus™ Reagent for HaCaT cells, and the 
calcium phosphate precipitation method for C33a cells. E2 function was determined 
by co-transfecting the reporter plasmids with increasing amounts of pCMV-E216 (up 
to 10ng) or with a fixed amount (1ng) of pCMV-E216 and increasing amounts of p16-
HAL2, p16-L2 or p16-L2 deletion mutants (0.01μg – 1μg). Total amount of DNA 
was adjusted to 2μg with pCMV4. Cells were harvested 48 hours post-transfection and 
luciferase assays were performed according to the manufacturer’s instructions 
(Promega, UK). 
2.6. Transient DNA replication assays. Transient DNA replication assays were 
performed in C33a cells, as first described by Sakai and colleagues (Sakai et al., 
1996) and as modified by Boner et al. (Boner et al., 2002). Cells were set up in 
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100mm plates at 6x105 per plate and transfected with 1μg p16ori-m, 5μg pCMV-E116, 
10ng or 100ng pCMV-E216 with or without 1μg or 2μg p16-HAL2 using calcium 
phosphate precipitation for C33a cells or Lipofectamine Plus™ Reagent method for 
HaCaT cells, respectively. Low molecular weight DNA was extracted using the Hirt 
protocol (Hirt, 1967) modified as described below. Three days after transfection, cells 
were washed twice with PBS and lysed in Hirt solution (0.6% SDS, 10mM EDTA). 
NaCl was added to 1M final concentration, and the lysates were left overnight at 4oC. 
Samples were centrifuged at 15000g for 30minutes at 4oC, the supernatant, containing 
low molecular weight DNA, was retained, extracted with phenol-chloroform and 
DNA precipitated with ethanol. To create linearised plasmid, 25μl of each sample 
were digested with 20U Xmn I for 3 hours at 37oC.  Linearised plasmid was further 
digested with 20U Dpn1 overnight at 37oC. As Xmn I linearises p16ori-m while Dpn I 
distinguishes replicated from unreplicated DNA, replication was assayed after Xmn I 
and Dpn I digestion. DNA was electrophoresed in a 1% agarose gel in 0.5x TBE and 
transferred to a Hybond-N nylon membrane (Amersham Pharmacia Biotech) by 
Southern blotting. Hybridisation was done using QuikHyb hybridisation solution 
(Stratagene Europe) according to the manufacturer’s instructions. A Molecular 
Dynamics Storm 840 (Amersham Pharmacia Biotech) phosphorimager was used to 
scan the Southern blot and quantify hybridised signals. The extent of replication was 
calculated by measuring the ratio of double cut/single cut bands. This method of 
measurement controls for variation in transfection efficiency between experiments.  
2.7. Probe for hybridisation. The p16ori-m (2μg) plasmid was digested with Pvu II. 
The digest was run down in a 1% agarose gel and a band of ~700bp, corresponding to 
the sequence of HPV16-ori, was cut out. It was purified using the QIAquick™ Gel 
Extraction kit (Qiagen, UK) and eluted in 60μl dH2O. A Prime-it II Random labelling 
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kit (Stratagene Europe) with α32PdCTP was used to generate the probe according to 
the manufacturer’s instruction and purified using a NICK Column (Amersham 
Pharmacia Biotech, UK).   
2.8. Real Time Quantitative PCR. HaCaT cells were seeded and transfected with 
4μg pCMV-E216 and/or 4μg p16-HAL2 as described above for Western blot, and total 
RNA was isolated with RNeasy®MiniKit  (Qiagen, UK) and resuspended in RNase-
free water following the instructions of the supplier. Thirty-two ng total RNA was 
digested with 0.5U DNAse I (Invitrogen™, UK) according to the manufacturer’s 
protocol. The reverse transcription was primed in duplicate with Random Primers 
(Promega, UK) at a concentration of 0.5μg in a 25μl reaction mixture with or without 
3U AMV-RT and 0.5mM each dNTP, 20U rRNAsin, and 1X AMV-RT buffer (all 
from Promega) following the instructions of the supplier. As a preliminary screening, 
the products of the reactions with or without AMV-RT were amplified by PCR with 
2.5U Taq Polymerase (Gibco BRL®, UK) in a final volume of 50μl containing 1X 
PCR buffer (Gibco BRL®, UK), 125μM of each dNTP (Promega, UK) and 0.5μM of 
each primer (sense: 5’CGA TGG AGA CTC TTT GCC AA; antisense: 5’TAT AGA 
CAT AAA TCC AGT) for 30 cycles at 94ºC 1 min, 50ºC 1 min and 72ºC for 2 min 
and 1 cycle at 72ºC for 10 min and the PCR products were electrophoresed in a 1% 
agarose gel. Once confirmed that the RNA was free from DNA contamination, cDNA 
was amplified in triplicate with the primers Tq16E2f 5’CCT GAA ATT ATT AGG 
CAG CAC TTG and Tq16E2r 5’GCG ACG GCT TTG GTA TGG at a concentration 
of 300mM each in a 50μl reaction that contained in final concentration: 1X PCR 
Buffer II, 200μM dATP, dCTP, dGTP, and 400μM dUTP, 5.5mM MgCl2 and 1.25U 
AmpliTaq® DNA Polymerase with GeneAmp®. The reaction also contained the 
detection probe TaqMan® Probe: 5’ CAA CCA CCC CGC CGC GA, at a 
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concentration of 300nM. The thermal cycling conditions were 2 min at 95°C, 
followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. All reactions were 
performed in the model 7700 Sequence Detector (PE Applied Biosystems, UK), 
which contains a GeneAmp PCR System 9600. As control cDNA was amplified with 
primers for actin: β-actin Forward Primer and β-actin Reverse Primer (PE Applied 
Biosystems, UK) at a concentration of 60nM each in a reaction mix as described for 
E2 and with the same cycling conditions, with β-actin Probe (PE Applied Biosystems, 
UK) at a concentration of 40nM. 
2.9. Detection of GFP fusion proteins. HaCaT cells were seeded onto nº 01 
coverslips in 24-well plates at a density of 105 cells/well and cultured overnight. 
When 80% confluent, cells were transfected with 0.1μg of either pEGFP-L2 or 
pEGFP-L2 deletion mutants, or with control empty plasmids (pEGFP-C1), using 
Lipofectamine Plus™ Reagent according to the manufacturer’s instructions. Twenty-
four hours after transfection, the cells were washed twice with PBS and fixed by 10-
min incubation at room temperature with 1.85% formaldehyde diluted in PBS 
containing 2% sucrose, and washed three times with PBS. Cells were incubated with 
4’6’-Diamino-2-phenylindole (DAPI) for 10mins, to stain the nucleus, washed in 
PBS-FCS and then distilled water, dried and mounted in AF1 (Citifluor, UK). Cells 
were analysed with a Leica TCS SP2 true confocal scanner microscope (Leica-
microsystems, Heidelberg Germany). Images were merged and acquired using Leica 
confocal software. 
2.10. Expression and purification of GST fusion proteins. Colonies of E. coli 
BL21 containing recombinant pGEX-GST-L2 fusion expression vectors were grown 
at 37oC with shaking until an absorbance of 0.6-0.8 at 600nm was reached. 
Expression was induced by the addition of IPTG (final conc. 0.4-0.1mM). Bacteria 
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were pelleted and resuspended in 5ml of BugBusterTM Protein Extraction Reagent 
(Novagen, Merck, UK) containing 1 tablet protease inhibitor cocktail per 10ml 
reagent, and incubated for 30min. The cell extracts were centrifuged at 2500g for 
30min. 1ml aliquots of the supernatant were transferred to fresh tubes and stored at –
70oC. Fusion proteins were purified on glutathione-Sepharose beads by incubating 
1ml supernatant with 50μl beads for 30 min at room temperature with rotation. The 
beads were pelleted in a microfuge (14000 rpm, 20 sec) and washed three times with 
0.5 ml NETN (20mM Tris-HCL, pH 8.0), 100mM NaCl, 1mM EDTA, 0.5% Nonidet 
P-40 (NP-40) containing 1 tablet protease inhibitor cocktail per 10ml buffer. The 
beads were resuspended in 50μl NETN and purified proteins were analysed by 10% 
SDS-PAGE before subsequent manipulations. 
2.11. In vitro transcription/translation of E2.  HPV-16 E2 ORF was subcloned 
from pCMV-HPV16 E2 into the BamHI site of pBluescript SKII under control of the 
T7 promoter using standard molecular biology techniques. HPV-16 E2 was in-vitro 
transcribed-translated using TNT Quick Coupled Transcription/Translation System 
(Promega, UK) as instructed by the manufacturer to produce 35S-methionine labelled 
E2. The efficiency of transcription-translation was checked using a luciferase control 
plasmid construct to produce 35S labelled luciferase. 5μl of each reaction was analysed 
by SDS-PAGE and the gel was fixed in 7% methanol and 7% glacial acetic acid for 
15min shaking and 10minutes with AmplifyTM Fluorographic reagent (Amersham 
Pharmacia Biotech, UK). The gel was dried and exposed for autoradiography at –
70oC overnight.  
2.12. GST pull-down assays for L2-E2 interaction. GST pull-down assays were 
performed as follows: pGEX, pGEX-L2 and pGEX-L2 deletion mutant proteins were 
expressed and purified as described above. The proteins immobilised on beads were 
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pre-washed three times in pull-down buffer (PDB: 50mM Tris pH 7.9, 100mM NaCl, 
1mM DTT, 0.5mM EGTA, 0.5% NP-40, 1mM PMSF). 7.5μl 35S labelled E2 was 
incubated with approximately 1μl bead-immobilised fusion protein in a total volume 
of 200μl fresh PDB for 30 min at 4oC with rotation. The beads were pelleted in a 
microfuge (14000 rpm, 10sec) and washed four times in PDB. Bound proteins were 
separated by 10% SDS-PAGE, fixed, the gel was dried and exposed for 
autoradiography at –70oC overnight. Bands were then analysed by densitometry using 
a UMAX Powerlook III Flatbed scanner and ImageQuant v5.2 software. 
 
3.  Results 
It has been reported that L2 localises to ND10 in the BPV-1, HPV-11 and 
HPV-33 systems (Day et al., 1998; Florin et al., 2002; Heino et al., 2000) and, in 
BPV-1, directs E2 to ND10 (Day et al., 1998; Heino et al., 2000). We asked how 
HPV-16 E2-L2 interaction would affect E2 functions and investigated it in HaCaT 
and C33a cells. HaCaT cells are spontaneously immortalised keratinocytes containing 
no HPV genes, while C33a cells are derived from an HPV-negative cervical cancer.   
3.1.  HPV-16 L2 down-regulates the transactivation function of E2. To investigate 
whether the HPV-16 E2 and L2 proteins interact, and what effect this interaction 
would have on the transcription transactivation function of E2, we used the luciferase 
reporter plasmids p18-LCR-BS1 and p18-LCR-BS1-3 in which either BS1 or BS1-3 
are mutated (Figure 1A). These mutant forms of the HPV18 LCR were chosen as they 
are transactivated by E2 in contrast to wild type LCR which is repressed by E2 
(Demeret et al., 1997). We also used p18-6E2 and ptk6E2, two minimal promoter 
constructs, containing six E2 binding sites, expressing luciferase under the control of 
the HPV-18 promoter or the tk promoter, respectively (Figure 1A), which are 
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transactivated by E2 (Vance et al., 1999). Each reporter plasmid was co-transfected 
with increasing amounts of pCMV-E216 in HaCaT and C33a cells. In all cases, 
luciferase expression increased with increasing amounts of E2 and there was no trans-
repression even at the highest amounts of E2 used (Figure 1B).  
The effect of E2-L2 interactions on the transactivation functions of E2 was 
investigated by co-transfecting increasing amounts (up to 0.5μg) of p16HAL2 or 
p16L2 with constant amounts of luciferase reporter (0.1μg) and of pCMV-E216 (1ng) 
in either HaCaT or C33a cells. pCMV-E216 was kept constant at 1ng as this amount is 
sub-optimal for E2-mediated trans-activation thus allowing the detection of any effect 
of L2. The addition of L2 led to an inhibition of E2-mediated transactivation in a 
dose-dependent manner in both cell lines (Figures 1C). This was observed for all 
reporter plasmids, although the kinetics of inhibition varied slightly from reporter to 
reporter. All reporters were however fully inhibited at the highest amounts of L2 used. 
The addition of L2 in the absence of E2 did not affect the constitutive activity of the 
reporters (Figure 1C), nor did it affect promoters not responsive to E2 (data not 
shown). We conclude that L2 inhibits the transactivation function of E2. Co-
expression of L2 and E2 did not relieve trans-repression of the wild type LCR by E2 
(data not shown).  
3.2. HPV-16 L2 does not down-regulate the viral replication function of 
E2. E2 binds to E1 and promotes origin-dependent viral DNA replication. We 
examined the effect of L2 on the ability of E2 to co-operate with E1 in a transient 
DNA replication assay. The DNA replication assays were performed in C33a; 
replication assays did not work in HaCaT cells, perhaps due to a decrease in 
cdk2/cyclin E activity as described for HeLa cells (Lin et al., 2000). A representative 
replication assay is shown in Figure 2A. DNA replication was dependent on the 
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presence of p16ori-m, E1 and E2. In the absence of E2, no replication took place, 
while at 10ng of E2 a replicated band was detected, increasing with increasing E2 
concentrations (Figure 2A, cf. lanes 6 and 12). There was no replication in the 
presence of L2 and absence of E2 (Figure 2B). To compare different experiments, the 
blots were quantified by scanning the membranes and the ratio between replicated and 
input DNA was measured for three experiments. Replication in absence of L2 was 
taken as 1; the expression of L2 did not appreciably affect replication and the small 
difference was not statistically significant (Figure 2B). These results demonstrate that, 
whereas L2 had little effect on the replication activity of E2 as shown for BPV-1 
(Heino et al., 2000), it drastically inhibited the transcriptional function of E2. 
3.3. Co-transfection with L2 induces down-regulation of E2. Co-expression of the 
L2 and E2 genes in HaCaT cells transiently co-transfected with both E2 and L2 
plasmids was ascertained independently by detection of L2 and E2 RNA by RT-PCR 
(L2, data not shown; E2, Figure 4B) and expression of L2 and E2 proteins by Western 
blots (Figure 3A). E2 levels were greatly reduced when co-expressed with L2, 
compared to E2 levels when expressed on its own (Figure 3A).  
However, when the same experiment was repeated in C33a cells transiently 
co-transfected with E2 and L2 plasmids, no decrease in E2 levels was observed in 
cells expressing L2 (Figure 3B). Therefore, L2-induced E2 down-regulation seems to 
be cell type-dependent.  
These results allow us to conclude that L2-induced inhibition of E2 
transcription transactivation function is not due to the marked decrease in E2 levels, 
as a similar degree of transcriptional transactivation inhibition was observed in 
HaCaT and C33a cells independently of the amount of E2.  
 15
3.4. HPV-16 L2 down-regulates E2 in a proteasome independent manner. To 
investigate whether the reasons for L2-induced loss of E2 in HaCaT cells was due to 
protein degradation, transiently transfected HaCaT cells were treated with a panel of 
proteasome/protease inhibitors. While treatment with the inhibitors increased the 
amount of E2, it failed to restore E2 levels to those of control cells without L2 (Figure 
4A). Thus, although E2 levels are controlled by degradation through the proteasome, 
in agreement with previous results (Penrose and McBride, 2000), the decrease in E2 
amounts in L2-expressing HaCaT cells appears to be due to additional mechanisms. 
In contrast, in C33a cells the inhibitors increased the amount of E2 to approximately 
the same extent, whether L2 was present or not (Figure 4A). The reasons why there 
was no increase in E2 levels after ALLM treatment are not clear, but again E2 levels 
were constant irrespective of L2 expression.  
3.5. HPV-16 L2 does not alter HPV-16 E2 mRNA level. To ascertain whether the 
decrease in E2 protein in HaCaT cells expressing L2 was due, at least in part, to 
inhibition of E2 mRNA synthesis, HaCaT cells were transfected with 4μg pCMV-
E216 and/or 4μg p16-HAL2 as described above, and total RNA was isolated. The 
RNA preparations were analysed for E2 mRNA levels by Real Time Quantitative 
PCR. There was no difference in E2 mRNA levels in cells transfected with E2, or E2 
and L2 (Figure 4B), as all the amplification curves were coincident. Therefore we 
conclude that E2 mRNA level was not altered by the presence of L2, indicating that 
the observed L2-induced decrease in E2 takes place post-transcriptionally. 
3.6. Delineation of L2 domains responsible for inhibition and degradation of E2. 
To identify the domains of L2 responsible for the observed effects on E2 function and 
stability, we generated mutants with either the C-terminus or the N-terminus of L2 
deleted (Figure 5A). The corresponding deleted L2 ORFs were cloned in pGEX for 
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the production of GST-L2 fusion proteins to be used in mutant L2-E2 interaction 
studies, in pEGFP for the production of GFP-L2 fusion proteins to analyse mutant L2 
localisation studies and stability, and in pcDNA3 for expression in mammalian cells 
for transcriptional transactivation studies.  
GST-L2 proteins were expressed in E. coli and confirmed to be of the 
expected mobility (not shown). They were bound to glutathione-Sepharose beads and 
incubated with in vitro transcribed/translated 35S-E2. All the C-terminus deletion 
mutant of L2 bound E2, including L2(1-50) which contains only the first 50 amino 
acid residues of the protein (Figure 5B). In contrast, the N-terminus deletion mutants 
did not bind E2 to any appreciable extent over the background seen with GST alone 
(Figure 5B). We conclude that L2-E2 interaction is mediated by the very N-terminus 
of L2. No binding between E2 and luciferase was observed (data not shown), 
confirming the specificity of the interaction between L2 and E2.    
To investigate the effects of L2 deletion mutants on E2 functions, it was 
necessary to ascertain that L2 mutants localise in the nucleus and have similar 
expression levels. Nuclear localisation was investigated by using the GFP-L2 fusion 
proteins expressed in HaCaT keratinocytes. While GFP on its own localised both in 
the nucleus and the cytoplasm (Figure 6A), GFP-wt L2 (with or without the HA1 
epitope at its N-terminus) localised in the nucleus (Figure 6B). All the GFP-L2 C-
terminus deletion mutants had a predominantly nuclear localisation (shown for L2(1-
200) and L2(1-50) in Figure 6C and D respectively). In contrast, the GFP-L2 N-
terminus deletion mutants had a cytoplasmic and nuclear localisation not dissimilar 
from that of GFP alone (Figure 6E for L2(250-473)).  
Next we analysed the expression of GFP-L2 and GFP-L2 mutants in HaCaT 
cells by western blots using an anti HPV-16 L2 polyclonal rabbit serum (Gornemann 
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et al., 2002). Although degradation bands were present, the C-terminus deletion 
mutants L2(1-400), L2(1-300) and L2(1-200) showed similar levels of expression, 
higher than that of GFP-L2 (Figure 7A). The antibody did not however detect L2(1-
50) and was poor at detecting L2(1-100) perhaps because of the loss of reactive 
epitopes. Therefore the stability of these two proteins was established using the anti 
GFP polyclonal rabbit serum SC-8334 (Santa Cruz Biotechnology). Both fusion 
proteins were detected and appeared to be expressed at similar levels (Figure 7B). The 
L2 N-terminus deletion mutants did not appear to be stable as judged by the poor 
detection with both antisera. Given their inability to bind E2, disperse cellular 
localisation and instability, these mutants were not analysed further. 
Next we tested the effects of L2 C-terminus deletion mutants on the ability of 
E2 to trans-activate ptk6E2 in HaCaT cells. The transactivation activity of E2 was 
inhibited by wt L2 and by L2(1-400) (Figure 8A). The remaining L2 mutants did not 
inhibit E2 activity to any significant extent (Figure 8A). We conclude that the L2 
domain responsible for inhibition of E2 transactivation resides between residue 301 
and 400. Thus, although all the L2 C-terminus deletion mutants can bind E2 (Figure 
5B), binding is not sufficient for E2 inhibition.     
Finally, we investigated the ability of L2 mutants to induce E2 degradation. It 
was clear that only full length L2 reduced E2 levels and none of the L2 mutants 
retained this ability (Figure 8B). Thus binding of E2 by L2 is not sufficient to induce 
E2 degradation.  
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4. Discussion 
4.1. HPV-16 L2 inhibits the transcription transactivation function but not the 
DNA replication function of E2 . The results presented here demonstrate, for the 
first time, that HPV-16 L2 can repress the transcriptional activation properties of the 
HPV-16 transcription/replication factor E2 (Figure 1). At the same time they also 
show that the L2 protein has little effect on the ability of E2 to activate DNA 
replication in association with E1, the viral DNA replication factor (Figure 2). Similar 
conclusions have been drawn previously in the BPV-1 system (Heino et al., 2000). 
However there are clear differences between these two sets of results. Firstly, in the 
BPV-1 transcription assays the levels of L2 protein required to repress E2 
transactivation function also repressed the E2-responsive promoter, even in the 
absence of E2. Therefore it is difficult to conclude with certainty that L2 was 
repressing E2 function; any down-regulation of E2 activity could have been due to 
repression of the promoter itself. On the contrary, in our HPV-16 system the levels of 
L2 repressing E2 trans-activation (up to 0.5μg of transfected plasmid) had no effect 
on any of the E2-responsive promoters in the absence of E2. Therefore we can 
conclude with certainty that the presence of L2 is repressing the E2 transactivation 
function. Secondly, in the BPV-1 system L2 repressed the ability of E1 to activate 
replication whether E2 was present or not, and thus the results are not clearly 
interpretable. In our HPV-16 system, although E1 cannot activate DNA replication in 
the absence of E2, in the presence of L2 there is no repression of E1 and E2-mediated 
DNA replication. In conclusion, we have demonstrated clearly that HPV-16 L2 
inhibits the ability of HPV-16 E2 to activate transcription while having no effect on 
the ability of E2 to activate DNA replication in association with E1. 
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4.2. L2 inhibition of  E2 transcriptional transactivation function is not due to L2-
induced degradation of E2. We next investigated a possible mechanism for the 
inhibition of E2 transcriptional activation property. It seemed possible that L2 
expression could result in a decrease of E2 protein levels thus repressing the ability of 
E2 to activate transcription but allowing residual E2 to efficiently activate DNA 
replication. In HaCaT cells, L2 does indeed promote a noticeable reduction of E2 
levels (Figure 3A). However DNA replication assays do not work in these cells and 
therefore we could not determine whether the decrease of E2 protein levels resulted in 
repression of DNA replication. The mechanism of L2-induced reduction of E2 levels 
in HaCaT cells is not clear although it does not seem to be proteasome-dependent as 
treatment with proteasome inhibitors resulted in an elevation of E2 levels, as 
demonstrated previously (Penrose and McBride, 2000), but failed to restore them to 
normal amounts in the presence of L2 (Figure 4). In contrast, in C33a cells L2 
expression does not result in degradation of the E2 protein (Figure 3B) although L2 
can still repress the transcriptional transactivation function of E2. The difference 
between the two cell lines allows the conclusion that L2 can directly repress E2 
transcriptional activation function without necessarily degrading E2. This is also 
confirmed in HaCaT cells where the deletion mutant L2(1-400) can still repress E2 
transactivation function without degrading the E2 protein (Figure 8). The lack of any 
effect by L2 on the DNA replication function of E2 in C33a cells  also demonstrates 
that the effect of L2 on E2 functions is selective.  
4.3. Binding of L2 to E2 is not sufficient for functional or physical down-
regulation of E2. To investigate whether a direct interaction between E2 and L2 is 
responsible for repressing the E2 transactivation function, and to identify the 
responsible domains, a series of L2 deletion mutants were made. Amino acids 1-50 
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were all that was required for interaction with E2 in vitro (Figure 5). This portion of 
L2 includes the domain required for DNA binding (Zhou et al., 1994) and nuclear 
transport (Sun et al., 1995). In agreement, L2(1-50) was sufficient to direct the GFP 
protein into the nucleus (Figure 6). L2(1-50) however could not repress the ability of 
E2 to activate transcription, nor did it reduce the levels of E2 (Figure 8), showing that 
L2 binding of E2 in not sufficient for inhibition of E2 transcription transactivation 
function or for its physical down-regulation. Deletion of amino acids 301-400 
removed the ability of L2 to repress E2 transactivation function, suggesting that this 
domain interacts with proteins responsible for the inhibition of E2 transactivation 
function. This suggestion is supported by the observations that this region of L2 
overlaps with the ND10 localisation signal (390-420 aa; Becker et al., 2003) and that 
L2 interacts with the transcriptional repressor PATZ in ND10 (Gornemann et al., 
2002). It is therefore possible that the interaction of L2 with both E2 and PATZ (or 
other transcription repressors) in ND10 is responsible for the inhibition of E2 
transcriptional activation function. These points however require further investigation. 
 
5. Conclusions. 
The conclusion from these experiments is that L2 can directly interact with E2 
and while this may be necessary for the repression of E2 transactivation function, it is 
not sufficient for either the functional or physical down-regulation of E2 (Figure 8). 
Functional down-regulation of E2 is brought about by a C-terminal domain of L2 
between amino acid residues 301 and 400, whereas the decrease in E2 protein levels 
appears to require full length L2.    
We can also conclude that whatever the nature of the mechanism used by L2 
to repress E2 transcriptional function, this has little effect on DNA replication. It will 
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be of interest to identify the L2 interacting protein(s) responsible for mediating the 
repression of E2 transcriptional activation and this investigation is currently 
underway. 
The effect of L2 on E2 also has the potential to be crucial for regulation of the 
viral life cycle. Following L2 expression, E2 transcriptional functions would be 
repressed, allowing the protein to focus on DNA amplification in association with E1. 
Most of the DNA amplification occurs in the upper layers of the epithelium and is co-
incident with expression of the L2 protein. Whether viral DNA replication occurs in 
ND10 domains, to which L2 recruits E2, is currently under investigation. The L2-E2 
interaction requires further characterisation and is likely to be a target in anti-viral 
strategies if it is demonstrated to be essential for the viral life cycle. 
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Legends to figures.  
Figure 1. L2 inhibits the transcription transactivation function of E2. A, Schematic 
representation of luciferase reporter plasmids. The first three plasmids contain the 
wild type LCR of HPV-18 (pHPV18-LCR), the LCR with four point mutations in the 
E2 binding site 1 (pHPV18-LCR-BS1) or four point mutations in each of sites 1 to 3 
(pHPV18-LCR-BS1-3). The other two plasmids are p18-6E2 containing six E2 
binding sites upstream of the HPV-18 promoter and the E2-minimal promoter 
constructs ptk6E2, containing six E2 binding sites upstream of the tk promoter. B, 
Transactivation of HPV-18 LCR BS mutants and E2 minimal promoter constructs by 
HPV-16 E2 in HaCaT and C33a cells. Cells were transiently transfected with 0.1μg of 
each luciferase reporter construct and with increasing amounts (0, 0.01, 0.1, 1 and 
10ng) of the E2 expression plasmid pCMV-E216. The total amount of DNA was kept 
constant by adding appropriate amounts of the parental plasmid pCMV. Each 
experiment was performed at least three times in duplicate. Transactivation is shown 
as fold activation of luciferase expression over that of the reporter plasmids without 
E2 (black bars), taken arbitrarily as 1. Standard deviation (SD) is shown. C, HPV-16 
L2 down-regulates the transcription transactivation function of E2. HaCaT and C33a 
cells were transiently co-transfected with 0.1μg of each luciferase reporter construct 
and 1ng pCMV-E216 with increasing amounts of p16-L2, (0, 0.01, 0.05, 0.1 and 
0.5μg). Each experiment was adjusted for total DNA by co-transfecting with the 
parental plasmid pCMV. Each experiment was performed at least three times in 
duplicate. Transactivation is shown as fold activation of luciferase expression over 
that of the reporter plasmids without E2 (black bars), taken arbitrarily as 1. SD is 
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shown. The activity of the promoters with no E2 and 0.5μg of L2 is shown as light 
grey bars.  
Figure 2. HPV-16 L2 does not affect the replication function of HPV-16 E2 in C33a 
cells. (A) Phosphorimage of a Southern blot hybridised with 32P-labelled HPV-16 ori 
plasmid. Cells were transfected with 1μg of p16ori-m, +/- 5μg pCMV-E116, +/- 10ng 
or 100ng pCMV-E216 and +/- 1μg or 2μg pL2. For each reaction, Xnm1 was used to 
linearise p16ori-m (odd-numbered lanes) and then Dpn1 was used to digest replicated 
DNA (even-numbered lanes). The open arrow on the left indicates input plasmid; the 
full arrow on the right indicates the replicated plasmid. Replication occurred in the 
presence of 10ng or 100ng of pCMV-E216 co-transfected with 1μg p16ori-m and 5μg 
pCMV-E116 (lanes 6 and 12). The absence of either E1 (lane 4) or E2 (lane 2) resulted 
in no detectable replication. The experiment was carried out three times with 
essentially the same results. (B) Quantitation of DNA replication. Southern blots were 
scanned and the extent of DNA replication was calculated by measuring the ratio of 
double cut/single cut bands, thus controlling for variations between experiments. The 
graph represents a summary of three independent experiments +/- standard deviation. 
Figure 3. HPV-16 L2 induces the degradation of E2 in HaCaT cells but not in C33a 
cells. (A), HaCaT cells were transfected with 4μg pCMV-E216 (lane 1), or 4μg 
pCMV-E216 plus 4μg p16-HAL2 (lane 2), or with 4μg p16-HAL2 alone (lane 3). (B), 
C33a cells were transfected with 4μg pCMV-E216 (lane 1), or 4μg pCMV-E216 plus 
4μg p16-HAL2 (lane 2). Cell extracts were analysed in independent Western blots 
with mouse anti-HA monoclonal antibody HA.11, anti-E2 mouse monoclonal 
antibody TVG261 and mouse anti-actin antibodies.  
Figure 4. HPV-16 L2 decreases the level of E2 in HaCaT cells in a proteasome 
independent manner without down-regulation of E2 transcription. (A) HaCaT cells or 
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C33a cells were transiently transfected with 4μg pCMV-E216 alone (“minus” lanes) or 
with 4μg pCMV-E216 and 4μg pL2 (“plus” lanes). Twenty four hours later the 
transfected cells were either treated for 8hr with the indicated proteasome inhibitors or 
kept untreated. Cells were lysed and the extracts were analysed by Western blot with 
mouse anti-HPV-16 E2 and mouse anti-actin antibodies. (B) Total RNA from HaCaT 
cells transfected with HPV-16 E2 alone or with HPV-16 E2 and HPV-16 L2 was 
digested with DNAse and reverse transcribed with random primers. Real time PCR 
was performed in triplicate with primers and probes for E2 and actin. There was no 
difference in E2 transcription in the presence or absence of L2 and all the 
amplification curves are coincident. 
Figure 5. The N-terminus of L2 interacts physically with E2. (A), Diagrammatic 
representation of C-terminus and N-terminus deletion mutants of E2. (B), GST-
mutant L2 fusion proteins were loaded onto glutathione beads and 10μl of 
immobilised beads were incubated with 35S-labelled E2. Bound proteins were 
separated by SDS-PAGE and visualised by autoradiography.  
Figure 6. L2 C-terminus, but not N-terminus, deletion mutants localise to the nucleus. 
100ng each of plasmids encoding GFP, GFP-wt L2 or GFP-L2 mutant proteins were 
transfected into HaCaT keratinocytes. Twenty four hr after transfection cells were 
fixed and stained for DNA using DAPI. Cells were analysed in a Leica TCS 
SP2confocal microscope.  
Figure 7. Expression of GFP-L2 C-terminus deletion mutants. Plasmids encoding 
GFP, GFP-L2 and GFP-L2 C-terminus deletion mutants (4μg) were transfected into 
HaCaT keratinocytes. Cells were lysed twenty four hours later and protein lysates 
were analysed by western blots with anti HPV-16 L2 polyclonal rabbit serum 
(Gornemann et al., 2002) (lanes 1-4) or anti GFP polyclonal rabbit serum SC-8334 
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(Santa Cruz Biotechnology, UK) (lanes 1-7). The arrowheads on the left point to the 
fusion proteins and the arrowheads on the right represent MW markers. 
Figure 8. Residues 301-400 of L2 inhibit E2 transactivation function but the full 
length protein is needed to induce E2 down-regulation. (A), 0.1μg of ptk6E2, 1ng of 
pCMV-E216 and increasing amounts (0.1-1μg) of each plasmid encoding C-terminus 
deletion mutants of L2 were co-transfected into HaCaT cells and luciferase activity 
measured as above. The experiment was repeated three times in duplicate and SD is 
shown. (B), 4μg pCMV-E216 were transfected into HaCaT keratinocytes with or 
without 4μg p16-L2 or 4μg of each plasmid encoding L2 C-terminus deletion 
mutants. One day later the transfected cells were lysed and the cell extracts were 
analysed by Western blot with mouse anti-HPV-16 E2 and mouse anti-actin 
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